Drug intelligence / Profile preview

KR11

Development stage: Preclinical
Lead developer: SPH Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

KR11 is an oncolytic virus vaccine derived from the wild-type herpes simplex virus (HSV-1, F strain), engineered with the insertion of Green Fluorescent Protein (GFP). It serves as a control group in preclinical studies evaluating the efficacy of KRAS-mutant oncolytic virus vaccines, such as KR10, for the treatment of metastatic colorectal cancer. While it possesses the inherent oncolytic properties of its viral backbone, its primary role in the described context is for research and control purposes rather than direct therapeutic application.

Beyond the preview

Go deeper on KR11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR11.

Explore the full profile